Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

Jeffrey A. Tornheim; Zarir F. Udwadia; Prerna R. Arora; Ishita Gajjar; Nikhil Gupte; Samridhi Sharma; Megha Karane; Namrata Sawant; Nisha Kharat; Alexander J. Blum; Shri Vijay Bala Yogendra Shivakumar; Jai B. Mullerpattan; Lancelot M. Pinto; Tester F. Ashavaid; Amita Gupta; Camilla Rodrigues

doi:10.1183/13993003.02511-2021

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

Jeffrey A. Tornheim, Zarir F. Udwadia, Prerna R. Arora, Ishita Gajjar, Nikhil Gupte, Samridhi Sharma, Megha Karane, Namrata Sawant, Nisha Kharat, Alexander J. Blum, Shri Vijay Bala Yogendra Shivakumar, Jai B. Mullerpattan, Lancelot M. Pinto, Tester F. Ashavaid, Amita Gupta, Camilla Rodrigues

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	2102511
Journal	European Respiratory Journal
Volume	59
Issue number	3
DOIs	https://doi.org/10.1183/13993003.02511-2021
State	Published - Mar 1 2022

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/13993003.02511-2021

Cite this

Tornheim, J. A., Udwadia, Z. F., Arora, P. R., Gajjar, I., Gupte, N., Sharma, S., Karane, M., Sawant, N., Kharat, N., Blum, A. J., Shivakumar, S. V. B. Y., Mullerpattan, J. B., Pinto, L. M., Ashavaid, T. F., Gupta, A., & Rodrigues, C. (2022). Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis. European Respiratory Journal, 59(3), Article 2102511. https://doi.org/10.1183/13993003.02511-2021

Tornheim, JA, Udwadia, ZF, Arora, PR, Gajjar, I, Gupte, N, Sharma, S, Karane, M, Sawant, N, Kharat, N, Blum, AJ, Shivakumar, SVBY, Mullerpattan, JB, Pinto, LM, Ashavaid, TF, Gupta, A & Rodrigues, C 2022, 'Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis', European Respiratory Journal, vol. 59, no. 3, 2102511. https://doi.org/10.1183/13993003.02511-2021

@article{a8f9889006064b33af0bf1caec8cb58f,

title = "Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis",

author = "Tornheim, {Jeffrey A.} and Udwadia, {Zarir F.} and Arora, {Prerna R.} and Ishita Gajjar and Nikhil Gupte and Samridhi Sharma and Megha Karane and Namrata Sawant and Nisha Kharat and Blum, {Alexander J.} and Shivakumar, {Shri Vijay Bala Yogendra} and Mullerpattan, {Jai B.} and Pinto, {Lancelot M.} and Ashavaid, {Tester F.} and Amita Gupta and Camilla Rodrigues",

note = "Funding Information: Conflict of interest: J.A. Tornheim reports, during the conduct of the study, salary support from NIH/NIAID (K23AI135102, R21AI122922 and R01AI134430), salary support from the NIH Fogarty International Center (R25TW009340) and salary support from the Johns Hopkins Clinician Scientist Career Development Award; salary support for a study clinician during the first year of the project was provided by the Frederick Mulder Foundation and the Pogge Tong Foundation. C. Rodrigues reports payment for manuscript writing, honoraria for lectures, educational events from Pfizer; honoraria for lectures from Cipla, Glenmark and Novartis; outside the submitted work. All other authors have nothing to disclose. Funding Information: Support statement: This work was supported by the NIH/DBT RePORT India Consortium with funding in whole or in part from the Government of India{\textquoteright}s (GOI) Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR), and distributed in part by CRDF Global. Additional support came from the National Health and Education Society, and the Indo-South African collaboration with funding from DBT and the Indian Department of Science and Technology (DST), as well as NIAID (K23AI135102, R21AI122922 and R01AI134430 to J.A. Tornheim, and UM1AI069465 to A. Gupta), the Office of the Director, Fogarty International Center, and Office of AIDS Research of the National Institutes of Health through the Fogarty Global Health Fellows Program Consortium (R25TW009340 to J.A. Tornheim), the Johns Hopkins University School of Medicine Clinician Scientist Career Development Award (to J.A. Tornheim), the Ujala Foundation, Gilead Foundation and Wyncote Foundation (to A. Gupta). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, DST, ICMR, NIH or CRDF Global. Any mention of trade names, commercial projects, or organisations does not imply endorsement by any of the sponsoring organisations. The funding sources had no role in the study design, data collection, data analysis, data interpretation or writing of the report. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: This work was supported by the NIH/DBT RePORT India Consortium with funding in whole or in part from the Government of India?s (GOI) Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR), and distributed in part by CRDF Global. Additional support came from the National Health and Education Society, and the Indo-South African collaboration with funding from DBT and the Indian Department of Science and Technology (DST), as well as NIAID (K23AI135102, R21AI122922 and R01AI134430 to J.A. Tornheim, and UM1AI069465 to A. Gupta), the Office of the Director, Fogarty International Center, and Office of AIDS Research of the National Institutes of Health through the Fogarty Global Health Fellows Program Consortium (R25TW009340 to J.A. Tornheim), the Johns Hopkins University School of Medicine Clinician Scientist Career Development Award (to J.A. Tornheim), the Ujala Foundation, Gilead Foundation and Wyncote Foundation (to A. Gupta). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, DST, ICMR, NIH or CRDF Global. Any mention of trade names, commercial",

year = "2022",

month = mar,

day = "1",

doi = "10.1183/13993003.02511-2021",

language = "English (US)",

volume = "59",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "3",

}

TY - JOUR

T1 - Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

AU - Tornheim, Jeffrey A.

AU - Udwadia, Zarir F.

AU - Arora, Prerna R.

AU - Gajjar, Ishita

AU - Gupte, Nikhil

AU - Sharma, Samridhi

AU - Karane, Megha

AU - Sawant, Namrata

AU - Kharat, Nisha

AU - Blum, Alexander J.

AU - Shivakumar, Shri Vijay Bala Yogendra

AU - Mullerpattan, Jai B.

AU - Pinto, Lancelot M.

AU - Ashavaid, Tester F.

AU - Gupta, Amita

AU - Rodrigues, Camilla

N1 - Funding Information: Conflict of interest: J.A. Tornheim reports, during the conduct of the study, salary support from NIH/NIAID (K23AI135102, R21AI122922 and R01AI134430), salary support from the NIH Fogarty International Center (R25TW009340) and salary support from the Johns Hopkins Clinician Scientist Career Development Award; salary support for a study clinician during the first year of the project was provided by the Frederick Mulder Foundation and the Pogge Tong Foundation. C. Rodrigues reports payment for manuscript writing, honoraria for lectures, educational events from Pfizer; honoraria for lectures from Cipla, Glenmark and Novartis; outside the submitted work. All other authors have nothing to disclose. Funding Information: Support statement: This work was supported by the NIH/DBT RePORT India Consortium with funding in whole or in part from the Government of India’s (GOI) Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR), and distributed in part by CRDF Global. Additional support came from the National Health and Education Society, and the Indo-South African collaboration with funding from DBT and the Indian Department of Science and Technology (DST), as well as NIAID (K23AI135102, R21AI122922 and R01AI134430 to J.A. Tornheim, and UM1AI069465 to A. Gupta), the Office of the Director, Fogarty International Center, and Office of AIDS Research of the National Institutes of Health through the Fogarty Global Health Fellows Program Consortium (R25TW009340 to J.A. Tornheim), the Johns Hopkins University School of Medicine Clinician Scientist Career Development Award (to J.A. Tornheim), the Ujala Foundation, Gilead Foundation and Wyncote Foundation (to A. Gupta). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, DST, ICMR, NIH or CRDF Global. Any mention of trade names, commercial projects, or organisations does not imply endorsement by any of the sponsoring organisations. The funding sources had no role in the study design, data collection, data analysis, data interpretation or writing of the report. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: This work was supported by the NIH/DBT RePORT India Consortium with funding in whole or in part from the Government of India?s (GOI) Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR), and distributed in part by CRDF Global. Additional support came from the National Health and Education Society, and the Indo-South African collaboration with funding from DBT and the Indian Department of Science and Technology (DST), as well as NIAID (K23AI135102, R21AI122922 and R01AI134430 to J.A. Tornheim, and UM1AI069465 to A. Gupta), the Office of the Director, Fogarty International Center, and Office of AIDS Research of the National Institutes of Health through the Fogarty Global Health Fellows Program Consortium (R25TW009340 to J.A. Tornheim), the Johns Hopkins University School of Medicine Clinician Scientist Career Development Award (to J.A. Tornheim), the Ujala Foundation, Gilead Foundation and Wyncote Foundation (to A. Gupta). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, DST, ICMR, NIH or CRDF Global. Any mention of trade names, commercial

PY - 2022/3/1

Y1 - 2022/3/1

UR - http://www.scopus.com/inward/record.url?scp=85127591800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127591800&partnerID=8YFLogxK

U2 - 10.1183/13993003.02511-2021

DO - 10.1183/13993003.02511-2021

M3 - Letter

C2 - 34949698

AN - SCOPUS:85127591800

SN - 0903-1936

VL - 59

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 3

M1 - 2102511

ER -

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this